196 related articles for article (PubMed ID: 36341492)
1. Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.
Sorger H; Dey S; Vieyra-Garcia PA; Pölöske D; Teufelberger AR; de Araujo ED; Sedighi A; Graf R; Spiegl B; Lazzeri I; Braun T; Garces de Los Fayos Alonso I; Schlederer M; Timelthaler G; Kodajova P; Pirker C; Surbek M; Machtinger M; Graier T; Perchthaler I; Pan Y; Fink-Puches R; Cerroni L; Ober J; Otte M; Albrecht JD; Tin G; Abdeldayem A; Manaswiyoungkul P; Olaoye OO; Metzelder ML; Orlova A; Berger W; Wobser M; Nicolay JP; André F; Nguyen VA; Neubauer HA; Fleck R; Merkel O; Herling M; Heitzer E; Gunning PT; Kenner L; Moriggl R; Wolf P
EMBO Mol Med; 2022 Dec; 14(12):e15200. PubMed ID: 36341492
[TBL] [Abstract][Full Text] [Related]
2. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
4. Targeting Phosphorylation of p21-activated Kinase 1 at Thr423 Induces Cell Cycle Arrest and Apoptosis in Cutaneous T-cell Lymphoma Cells.
Wang Y; Li W; Zhang Q; Gu X; He X; Men Y; Zhang C
Acta Derm Venereol; 2019 Oct; 99(11):1022-1028. PubMed ID: 31304555
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients.
Lin WM; Lewis JM; Filler RB; Modi BG; Carlson KR; Reddy S; Thornberg A; Saksena G; Umlauf S; Oberholzer PA; Karpova M; Getz G; Mane S; Garraway LA; Dummer R; Berger CL; Edelson RL; Girardi M
J Invest Dermatol; 2012 Jan; 132(1):188-97. PubMed ID: 21881587
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
7. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
8. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
10. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.
Zhang XH; Nam S; Wu J; Chen CH; Liu X; Li H; McKeithan T; Gong Q; Chan WC; Yin HH; Yuan YC; Pillai R; Querfeld C; Horne D; Chen Y; Rosen ST
J Invest Dermatol; 2018 Nov; 138(11):2377-2387. PubMed ID: 29758280
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
12. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.
Nielsen M; Nissen MH; Gerwien J; Zocca MB; Rasmussen HM; Nakajima K; Röpke C; Geisler C; Kaltoft K; Ødum N
Blood; 2002 Feb; 99(3):973-7. PubMed ID: 11807001
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
[TBL] [Abstract][Full Text] [Related]
15. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Clinical, histopathologic, and immunohistochemical analyses.
Nagatani T; Matsuzaki T; Iemoto G; Kim S; Baba N; Miyamoto H; Nakajima H
Cancer; 1990 Dec; 66(11):2380-6. PubMed ID: 2245393
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
[TBL] [Abstract][Full Text] [Related]
19. Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.
Bakr FS; Whittaker SJ
Front Oncol; 2022; 12():1043254. PubMed ID: 36505788
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Wu CH; Wang L; Yang CY; Wen KW; Hinds B; Gill R; McCormick F; Moasser M; Pincus L; Ai WZ
Blood Adv; 2022 Apr; 6(7):2290-2302. PubMed ID: 34872108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
